Erica Hill
Nurse Practitioner · Knoxville, TNNPI 1255968046
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 474 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 474 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$3K
- Novartis$2K
- Biogen$2K
- TG Therapeutics, Inc.$969
- Bristol Myers Squibb$820
- AstraZeneca$785
- plus $4K from 31 others
Across 10 payments — averaging $246.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
- Novartis Pharma AG$19
What the payments were for
- Consulting fees$1501%
- Travel & lodging$3823%
- Food & beverage$12,04094%
- Education$2702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 95 | $3,074 |
| Novartis | 56 | $1,792 |
| Biogen | 63 | $1,668 |
| TG Therapeutics, Inc. | 33 | $969 |
| Bristol Myers Squibb | 45 | $820 |
| AstraZeneca(2 entities) | 27 | $785 |
| Sanofi | 16 | $573 |
| Amgen | 12 | $480 |
| Genentech USA, Inc. | 21 | $458 |
| Otsuka America Pharmaceutical, Inc. | 19 | $386 |
| CSL Behring | 15 | $337 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $208 |
| Mallinckrodt Hospital Products Inc. | 7 | $179 |
| Cycle Pharmaceuticals Inc | 8 | $136 |
| Pfizer | 7 | $126 |
| Banner Life Sciences, LLC | 4 | $101 |
| Lundbeck LLC | 4 | $88 |
| Vanda Pharmaceuticals Inc. | 3 | $61 |
| Bard Peripheral Vascular, Inc. | 4 | $60 |
| Sandoz | 3 | $59 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Tersera Therapeutics LLC | 2 | $49 |
| Argenx US, Inc. | 2 | $45 |
| Averitas Pharma Inc. | 2 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Merz Pharmaceuticals, LLC | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| GE HealthCare | 1 | $24 |
| AbbVie | 1 | $18 |
| UCB, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,842 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 77 | $702,521 |
| VumerityDiroximel Fumarate | 36 | $312,826 |
| Plegridy PenPeginterferon Beta-1a | 34 | $277,215 |
| TecfideraDimethyl Fumarate | 13 | $120,814 |
| Dalfampridine ErDalfampridine | 83 | $56,164 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $27,267 |
| BelsomraSuvorexant | 13 | $5,851 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 91 | $2,919 |
| Modafinil | 62 | $2,799 |
| Baclofen | 118 | $1,977 |
| Gabapentin | 152 | $1,303 |
| Armodafinil | 22 | $1,220 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $1,130 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $835 |
| Teriflunomide | 20 | $804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tecfidera | $1,668 | $433,64049 claims |
| MerckBelsomra | $15 | $5,85113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Knoxville
- Karen RodenKnoxville$265K
- Erica HembreeKnoxville$125K
- Robin LovedayKnoxville$56K
- Tiffany SteelmanKnoxville$21K
- Jennifer BerryKnoxville$19K
- Amy HatcherMurfreesboro$1.1M
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Brooke FaughtNashville$87K
- Lauren WelchNashville$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.